L’Associazione Mario Coppo ONLUS si propone di incentivare la ricerca sulle malattie del fegato e di diffonderne i risultati a livello nazionale ed internazionale. Segue l’elenco dei più recenti contributi su prestigiose riviste scientifiche e a congressi nazionali ed internazionali.

Contributi scientifici a congressi

Efficacy and safety of increasing doses of the cyclophilin inhibitor Debio 025 in combination with pegylated interferon alpha 2° in treatment naive mono-Infected HCV patients.
43° Annual Meeting of the European Association for the Study of the Liver
(EASL) J Hepatol 48(S2): S62, 2008

Predicting the natural history of patients with hepatitis C and persistently normal transaminases: a longitudinal long term study with dual biopsies.
43° Annual Meeting of the European Association for the Study of the Liver
(EASL) J Hepatol 48(S2): S283, 2008

Long-term interferon therapy in patients with refractory chronic hepatitis C: effect on histological liver damage and hepatocellular carcinogenesis.
Hepatol Int 2: S122, 2008

Demographic, etiological and clinical features of liver cirrhosis at the onset of the first episode of clinical decompensation: Preliminary results of the A.I.S.F. EPASCO Study.
Digestive and Liver Disease 40(5):A10, 2008

Cytocheratin 19:an immunohistochemical marker to early detect Hepatocellular carcinoma with a more aggressive behaviour.
Digestive and Liver Disease 42(S1), S25; 2010

Better sustained control of chronic genotype 1 HCV infections with PEG IFN alfa-2a than with PEG IFN alfa 2b treatment:results
of daily clinical practice.
Digestive and Liver Disease 42(S1), S2-S3; 2010

IL- 6 polymorphisms paly a role in influencing the histological progression in patients with chronic HCV infection and normal
transaminases.
Digestive and Liver Disease 42(S1), S27; 2010

Predicting mortality risk in cirrhotic patients since the first decompensation based on a new prognostic score:The AISF-EPASCO prospective multicentre study.
Digestive and Liver Disease 42(S1);S3-S4, 2010

One-year mortality rate in patients with stage 3 and 4 cirrhosis:The Italian Association for the Study of Liver AISF-EPASCO Prospective multicentre study.
Digestive and Liver Disease 42(S1);S35, 2010

Low rate mortality in patients with stage 4 cirrhosis: the need of a reassessment of an old classification. The AISF-EPASCO Prospective multicentre study.
Hepatology 52(4S); 885A, 2010

Contributi Scientifici su riviste internazionali

The cyclophilin inhibitor Debio 025 combined with PEG IFNa2a significantly reduces viral load in treatment-naive hepatitis C patients.
Hepatology, 45:1460-1468, 2009

Genetic polymorphisms of interleukin-6 modulates fibrosis progression in mild chronic hepatitis C.
Human Immunology, 71(10):999-1004,2010

Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the “Cholangiocarcinoma”
Committee of the Italian Association for the Study of Liver Disease.
Digestive and Liver Disease, 43(1):60-65, 2011

Apolipoprotein E genotypes modulate fibrosis progression in patients with Chronic hepatitis C and persistently normal transaminases.
J. Gastroenterology and Hepatology, 26(2):328-333, 2011

Interleukin 28B rs 12979860 C/T polymorphism and serum Cholesterol as predictors of fibrosis progression in patients with chronic heaptits C and persistently normal transaminases.
Digestive and Liver Disease 43(S2);S79, 2011

Convegni internazionali
AASLD: American Association for the study of the liver

EASL: European Association for the study of the Liver